The Jiangxi Province Healthcare Security Administration has released a notification regarding the winning bids of the 16 – province (municipalities, regions) alliance volume – based procurement (VBP). The event, initiated on November 18, 2022, and led by Jiangxi, included Inner Mongolia, Jilin, Heilongjiang, Zhejiang, Henan, Hunan, Guangxi, Hainan, Chongqing, Guizhou, Shaanxi, Qinghai, Ningxia, Xinjiang, and the Xinjiang Production and Construction Corps. The procurement process affected 13 drugs that had failed to pass the generic quality consistency evaluation (GQCE).
Procurement Process and Evaluation Criteria
The VBP event comprehensively evaluated economical technical indicators and commercial indicators to determine the winning bids. The evaluation resulted in selecting bids with the lowest prices and highest marks, with secondary prices and marks chosen as backups. This rigorous evaluation process ensured that the selected bids met high standards of quality and cost – effectiveness.
Winning and Backup Manufacturers
Winning manufacturers included Brilliant Pharma, Minsheng Pharma, and Qilu Pharma. Backup selections involved Hengrui Medicine, Sihuan Pharma, and Otsuka Pharma. North China Pharma had two tendering products eliminated due to severe credit loss, and multiple manufacturers were not shortlisted due to undisclosed economic indicators. Bids for vitamin D and pancreatic kininogenase were aborted due to an inadequate number of bidders (3).-Fineline Info & Tech
